Clinical and research networks for rare conditions are increasingly common nowadays. Given the rarity of many such conditions, there is a need to cover more conditions, yet there is also a need to sustain and improve the quality and effectiveness of existing networks. This review will discuss the qualities that are required by a virtual network using some international clinical and research networks that are currently active in the field of rare endocrine conditions affecting sex and adrenal development as exemplars.

1.
Ahmed SF, Bryce J, Hiort O: International networks for supporting research and clinical care in the field of disorders of sex development. Endocr Dev 27:284-292 (2014).
2.
Ahmed SF, Achermann JC, Arlt W, Balen A, Conway G, et al: UK guidance on the initial evaluation of an infant or an adolescent with a suspected disorder of sex development (revised 2015). Clin Endocrinol (Oxf) 84:771-788 (2016).
3.
Cools M, Simmonds M, Elford S, Gorter J, Ahmed SF, et al: Response to the council of Europe human rights commissioner's issue paper on human rights and intersex people. Eur Urol 70:407-409 (2016).
4.
Hornig NC, Ukat M, Schweikert HU, Hiort O, Werner R, et al: Identification of an AR-mutation negative class of androgen insensitivity by determining endogenous AR-activity. J Clin Endocrinol Metab 101:4468-4477 (2016).
5.
Hughes IA, Houk C, Ahmed SF, Lee PA, LWPES consensus group; ESPE consensus group: Consensus statement on management of intersex disorders. Arch Dis Child 91:554-563 (2006).
6.
Kolesinska Z, Ahmed SF, Niedziela M, Bryce J, Molinska-Glura M, et al: Changes over time in sex assignment for disorders of sex development. Pediatrics 134:710-715 (2014).
7.
Kourime M, Bryce J, Jiang J, Karunasena N, Koehler B, et al: A new international registry highlights the differences in practice for reaching a diagnosis of CAH. ESPE Abstract 86 P-P1-356 (2016). Available at http://abstracts.eurospe.org/hrp/0086/hrp0086P1-P356.htm; last accessed April 26, 2017.
8.
Kourime M, Bryce J, Jiang J, Nixon R, Rodie M, Ahmed SF: An assessment of the quality of the I-DSD and the I-CAH registries international registries for rare conditions affecting sex development. Orphanet J Rare Dis 12:56 (2017).
9.
Kyriakou A, Dessens A, Bryce J, Iotova V, Juul A, et al: Current models of care for disorders of sex development - results from an International survey of specialist centres. Orphanet J Rare Dis 11:155 (2016).
10.
Lee PA, Nordenström A, Houk CP, Ahmed SF, Auchus R, et al: Global disorders of sex development update since 2006: perceptions, approach and care. Horm Res Paediatr 85:158-180 (2016).
11.
Polizzi A, Balsamo A, Bal MO, Taruscio D: Rare diseases research and practice. Endocr Dev 27:234-256 (2014).
12.
Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. OJ 18:1-5 (2000).
13.
Stell A, Sinnott R: The ENSAT registry: a digital repository supporting adrenal cancer research. Stud Health Technol Inform 178:207-212 (2012).
14.
Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, et al: The FAIR Guiding Principles for scientific data management and stewardship. Sci Data 3:160018 (2016).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.